Nuvectis Pharma Inc (NVCT)

Jan 01, 2025

(NVCT) Long Term Investment Analysis - Stock Traders Daily

Jan 01, 2025

Dec 29, 2024

Great week for Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders who have 63% stake and they haven’t stopped buying - Simply Wall St

Dec 29, 2024

Dec 26, 2024

Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Acquires 4,500 Shares - MarketBeat

Dec 26, 2024

Dec 26, 2024

Nuvectis Pharma CEO Ron Bentsur buys $20,925 in shares By Investing.com - Investing.com Australia

Dec 26, 2024

Dec 26, 2024

Nuvectis Pharma CEO Ron Bentsur buys $20,925 in shares - Investing.com

Dec 26, 2024

Dec 20, 2024

Nuvectis Pharma stock hits 52-week low at $4.44 amid market challenges - Investing.com Australia

Dec 20, 2024

Dec 16, 2024

Marlio Charles Mosseri Purchases 17,000 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock - MarketBeat

Dec 16, 2024

Dec 16, 2024

Nuvectis pharma investor Mosseri-Marlio purchases $79,900 in shares By Investing.com - Investing.com

Dec 16, 2024

Dec 10, 2024

Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium - The Manila Times

Dec 10, 2024

Dec 05, 2024

NVCT Stock Hits 52-Week Low at $4.61 Amid Market Challenges - Investing.com

Dec 05, 2024

Nov 26, 2024

Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know - MSN

Nov 26, 2024

Nov 25, 2024

Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - MSN

Nov 25, 2024

Nov 22, 2024

Nuvectis Pharma stock hits 52-week low at $4.7 amid market challenges - Investing.com Australia

Nov 22, 2024

Nov 22, 2024

Nuvectis Pharma stock hits 52-week low at $4.7 amid market challenges By Investing.com - Investing.com South Africa

Nov 22, 2024

Nov 21, 2024

Nuvectis sinks after early-stage data for ovarian cancer therapy - MSN

Nov 21, 2024

Nov 21, 2024

Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock By Investing.com - Investing.com Australia

Nov 21, 2024

Nov 21, 2024

Ron Bentsur Buys Handful Of Shares In Nuvectis Pharma - Simply Wall St

Nov 21, 2024

Nov 21, 2024

Insider Buying: Nuvectis Pharma Inc (NVCT) Chairman & CEO Acquires Shares - GuruFocus.com

Nov 21, 2024

Nov 20, 2024

Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock - Investing.com

Nov 20, 2024

Nov 19, 2024

Vitalli ends work on Daewoong asset; Alector’s $50M loan - Endpoints News

Nov 19, 2024

Nov 18, 2024

Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Buys 20,000 Shares - MarketBeat

Nov 18, 2024

Nov 18, 2024

Nuvectis pharma chairman buys $98,400 in common stock By Investing.com - Investing.com Canada

Nov 18, 2024

Nov 18, 2024

Nuvectis pharma chairman buys $98,400 in common stock - Investing.com

Nov 18, 2024

Nov 15, 2024

Nuvectis Pharma reports data from Phase 1b study of NXP800 - Yahoo Finance

Nov 15, 2024

Nov 14, 2024

Market Alert: Nuvectis Pharma reports promising data for NXP800 in Phase 1b; Advancing Towards Higher Dose Cohort - The Globe and Mail

Nov 14, 2024

Nov 14, 2024

500: Something went wrong - Investing.com Canada

Nov 14, 2024

Nov 14, 2024

Why Is Nuvectis Pharma Stock Trading Lower On Thursday?Nuvectis Pharma (NASDAQ:NVCT) - Benzinga

Nov 14, 2024

Nov 14, 2024

NVCT stock touches 52-week low at $5.05 amid market fluctuations - Investing.com India

Nov 14, 2024

Nov 14, 2024

U.S. Stock market: Nuvectis Pharma declined by 40.58% while Sow Good was down by 55.30% during mid day trading - Business Upturn

Nov 14, 2024

Nov 14, 2024

Nuvectis stock sinks on data for cancer drug (NVCT:NASDAQ) - Seeking Alpha

Nov 14, 2024

Nov 14, 2024

Nuvectis Pharma Stock Plummets on Updated Data for Ovarian Cancer Study - MarketWatch

Nov 14, 2024

Nov 14, 2024

Nuvectis Pharma Inc trading resumes - TipRanks

Nov 14, 2024

Nov 14, 2024

U.S. Stock market: Nuvectis Pharma saw a sharp decline of 53.89% while AgEagle Aerial Systems surged by 133.74% in early trading - Business Upturn

Nov 14, 2024

Nov 14, 2024

Nuvectis Pharma Reports Encouraging NXP800 Interim Data - GlobeNewswire

Nov 14, 2024

Nov 14, 2024

Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase - The Bakersfield Californian

Nov 14, 2024

Nov 14, 2024

Nuvectis Pharma's NXP800 Shows Promise in Phase 1b Cancer Trial, New Dosing Success | NVCT Stock News - StockTitan

Nov 14, 2024

Nov 14, 2024

Trading (NVCT) With Integrated Risk Controls - Stock Traders Daily

Nov 14, 2024

Nov 14, 2024

Nuvectis Pharma (NASDAQ:NVCT) Announces Third Quarter 2024 Financial Results and Business Updates - Defense World

Nov 14, 2024

Nov 13, 2024

Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance

Nov 13, 2024

Nov 08, 2024

Nuvectis Pharma's VP Michael Carson sells $22.5k in stock - Investing.com

Nov 08, 2024

Nov 08, 2024

Nuvectis Pharma's VP Michael Carson sells $22.5k in stock By Investing.com - Investing.com UK

Nov 08, 2024

Nov 08, 2024

FY2024 EPS Estimates for Nuvectis Pharma Raised by Analyst - Defense World

Nov 08, 2024

Nov 07, 2024

FY2024 EPS Estimate for Nuvectis Pharma Increased by Analyst - MarketBeat

Nov 07, 2024